drugset / Trial / NCT02693522

Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency

NCT02693522

Phase 3 Completed 52 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant human growth hormone on adult growth hormone deficiency

Timeline

Start
2003-10
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eutropin Protein / enzyme biologic Subcutaneous
Subject Somatropin Protein / enzyme biologic Subcutaneous

Indications